News Focus
News Focus
icon url

DewDiligence

05/07/22 2:11 PM

#242377 RE: dewophile #242373

CLVS—OS HR>1.0 is generally a deal-killer even when PFS is the primary endpoint.
icon url

DewDiligence

09/11/22 5:13 PM

#243799 RE: dewophile #242373

CLVS continues to show strong PFS data in ovarian cancer first-line-maintenance, while waiting for the OS data to mature; these results were presented as ESMO this weekend:

https://www.businesswire.com/news/home/20220911005019/en